金吾财讯 | 诺和诺德(NVO)盘前股价飙升，暂涨10.67%，报89.75美元。
公司今天公布了阿米克雷汀 (amycretin) 1b/2a 期临床试验的顶线结果。该试验研究了 125 名超重或肥胖患者每周皮下注射一次阿米克林后的安全性、耐受性、药代动力学和概念验证。
在评估所有患者遵循治疗的效果时，从平均基线体重92.7公斤开始，接受阿米克雷汀治疗的患者在1.25毫克剂量下（20周）实现了约9.7%的体重下降，在5毫克剂量下（28周）实现了16.2%的体重下降，在20毫克剂量下（36周）实现了22.0%的体重下降。相比之下，接受安慰剂治疗的患者分别经历了1.9%、2.3%和2.0%的体重增加。
诺和诺德公司开发执行副总裁马丁·朗格 (Martin Lange) 表示：“阿米克汀在超重或肥胖人群中的皮下 1b/2a 期结果令我们非常鼓舞。试验结果支持了这种新型单分子 GLP-1 和胰岛淀粉样肽受体激动剂阿米克汀的减肥潜力，我们之前已在口服制剂中看到这种潜力。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.